AndrewZhuangWangMD(He/Him)

Gastrointestinal Cancer, Urologic Cancer

A. Kenneth Pye Professor in Cancer Research Vice Chair of Translational Research and commercialization Department of Radiation Oncology UT Southwestern Medical Center

Join to view full profile

Dr. Wang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wang's full profile

Already have an account?

Office
5323 Harry Hines Boulevard
Dallas, TX 75390
Phone+1 214-645-8525

Fax+1 214-645-8526

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Radiation Oncology, 2009
Icahn School of Medicine at Mount Sinai/Morningside/WestInternship, Internal Medicine, 2004 - 2005
Harvard Medical SchoolClass of 2004

Certifications & Licensure

NC State Medical License 2009 - 2025
TX State Medical License 2021 - 2025
MA State Medical License 2006 - 2009
American Board of Radiology Radiation Oncology

Awards, Honors, & Recognition

Fellow American Society for Clinical Investigation, 2019
Fellow The American Institute for Medical and Biological Engineering (AIMBE), 2018
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Howard Hughes Medical Student Research Fellowship Howard Hughes Medical Institute
Join now to see all

Clinical Trials

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer Start of enrollment: 2009 Sep 01
Active, not recruiting
Phase 3
Safety, Efficacy, and Dosing of Stereotactic Radiosurgery for Hepato-cellular Carc/Colo-rectal Liver Metastases Start of enrollment: 2009 Apr 01
Completed
Not Applicable
PET/MRI as a Predictor of Response to Pre-op Chemoradiation in Resectable Rectal Cancer: a Pilot Study Start of enrollment: 2012 Oct 01
Completed
Cardiovascular Risk and Preventive Care in Prostate Cancer Patients Receiving Radiation and Hormone Therapy Start of enrollment: 2012 Jun 01
Completed
Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer Start of enrollment: 2013 Dec 01
Terminated
Phase 1, Phase 2
Using Walk With Ease Walking Program With Men 65 and Older Being Treated for Prostate Cancer Start of enrollment: 2013 Oct 01
Terminated
Join now to see all

Publications & Presentations

PubMed

202 citations
Antibody conjugated magnetic iron oxide nanoparticles for cancer cell separation in fresh whole blood
Hengyi Xu, Zoraida P. Aguilar, Lily Yang, Min Kuang, Hongwei Duan
Biomaterials. 2011-12-01
24 citations
Ultrashort Echo Time (UTE) imaging of receptor targeted magnetic iron oxide nanoparticles in mouse tumor models
Liya Wang, Xiaodong Zhong, Weiping Qian, Jing Huang, Zehong Cao
Journal of Magnetic Resonance Imaging. 2014-11-01
636 citations
Self-assembled lipid--polymer hybrid nanoparticles: a robust drug delivery platform.
Liangfang Zhang, Juliana M. Chan, Frank X. Gu, June-Wha Rhee, Andrew Z. Wang
ACS Nano. 2008-08-05

Books/Book Chapters

The Textbook of Prostate Cancer
Chapter: Definitions of Biochemical Failure
Zhang T, Wang AZ.Springer2013
Safety of Nanoparticles
Chapter: Nanoparticles for cancer diagnosis and therapy. Chapter: Nanoparticles for Cancer Diagnosis and Therapy.
Wang AZ, Gu FX, Farokhzad OC.Springer Science+Business Media, LLC2009
Bio-inspired Nanotechnology and Nanomaterials
Chapter: Biologically Targeted Nanoparticles as Cancer Therapeutics
Wang AZ, Radovic-Moreno AF, Farokhzad OC.Nova Science Publishers2009
Underground Clinical Vignettes USMLE Step 2: Surgery.
1. Kim, S.I., Swanson, T.A., Wang, AZ.Editors: 1. Kim, S.I., Swanson, T.A., Wang, AZ..Lippincott Williams & Wilkins/Wolters Kluwer HealthEdition 4,2007
Join now to see all

Lectures

Nanomedicine approaches to chemoradiation
Gordon Conference: Cancer Nanotechnology - 2013
Plenary speaker: Reformulating failed drugs using nanoparticles
National Cancer Institute Centers for Nanotechnology Excellence Principle Investigators Meeting - 2013
Nanomedicine to improve chemoradiotherapy
Dartmouth College Cancer Nanotechnology Symposium: Immuno Targeting and Delivery - 2013
Chemoradiotherapy: Novel Approaches from Nanomedicine
School of Pharmacy, University of Georgia, Athens, Georgia. - 2012
Nanomedicine and Radiation Oncology (Session co-chair)
Engineering in Medicine and Biology Conference, Institute of Electrical and Electronics Engineers. - 2012
The National Academies - Keck Futures Initiative-Imaging Science Conference
Keck Center - 11/2011
Join now to see all

Other

Drug delivery system for pharmaceuticals and radiation
Wang AZ, Farokhzad OC, Zhang LF, Radovic-Moreno A, Gu F, Langer R.
International PCT Patent Application No.: PCT/US08/082655
Delivery for brachytherapy and associated methods.
Wang Z, Werner M, Chen R, Byrne J, Karve S, Desimone J.
International PCT Patent Application No.: PCT/US2010/053357
Novel Wortmannin Nanoparticles and Uses Thereof.
Wang Z, Pacold M, Werner M, Karve S.
US PCT/US2011/ 61431689
Biomatrix Scaffolds
Wang Y, Reid LM, Yamauchi M, Cui C, Wang AZ, Werner M.
PCT/US11/42805
Join now to see all

Press Mentions

UT Southwestern Develops Nanotherapeutic to Ward off Liver CancerJanuary 14th, 2022
Researchers Study Strategies for Using Nanotechnology to Boost Cancer TherapeuticsApril 23rd, 2019
Improved Capture of Cancer Cells Could Aid in Disease TrackingMarch 15th, 2018

Grant Support

Development of 3D organ-specific models of colorectal cancer metastasisNational Institutes of Health/National Cancer Institute2013–Present
Nanoparticle formulations of DNA repair inhibitors to improve chemoradiotherapyNational Institutes of Health/National Cancer Institute2013–Present
Center for Cancer Nanotechnology ExcellenceNational Institutes of Health/National Cancer Institute2010–Present
Development of nanoparticle formulations of DNA double-strand break repair inhibitors to improve chemoradiotherapyLung Cancer Research Foundation2012–2013
Development of Nanoparticle-based Multiplex Multimodality Imaging Agents for the Specific and Sensitive Detection of CancerNational Academies of Science-Keck Futures Initiative Imaging Science2011–2013
Multifunctional Targeted Theranostic Nanoparticles Delivering Gemcitabine Triphosphate and IndiumNational Institutes of Health2011–2012
Particle Loaded Spacers for Prostate Cancer BrachytherapyUniversity of North Carolina Cancer Research Fund2010–2012
Particle-loaded spacers for prostate cancer brachytherapyNational Institutes of Health/National Cancer Institute2010–2012
Development of molecularly targeted nanoparticles for the delivery of radiosensitizersTriad Golfers Against Cancer2010–2011

Research History

Postdoctoral FellowResearch Fellow, Robert Langer, D.Sc./Omid Farokhzad, M.D. HST/Harvard-MIT Center for Nanotechnology Excellence, Cambridge, MA2006 - 2009

Professional Memberships

Other Languages

Chinese (Mandarin)

Industry Relationships

Research Support, Varian2020 - Present
Co-Founder and Board Member, Archimmune Therapeutics2019 - Present
Co-founder and CEO, Capio Bioscience2014 - Present
Research support, Accuray2015 - 2017
Consultant, Cerulean Pharma2014 - 2016
Consultant, Samyang Biopharmaceuticals, INCEvaluate nanoparticle formulation of docetaxelDisclosure: consulting fee2011 - 2012